Stop DAPT and Enoxaparin Immediately in Acute Cardioembolic Stroke
In a patient with acute cardioembolic stroke involving the right MCA who is on enoxaparin and DAPT, you must stop ALL antithrombotic therapy immediately—discontinue both the enoxaparin and both antiplatelet agents. The patient will need anticoagulation for the cardioembolic source, but this should be delayed to avoid hemorrhagic transformation.
Rationale and Management Algorithm
Immediate Actions (Day 0)
- Stop enoxaparin immediately - no role for therapeutic anticoagulation in acute stroke phase
- Stop both antiplatelet agents (aspirin and P2Y12 inhibitor) - DAPT dramatically increases hemorrhagic transformation risk in acute stroke
- Hold all antithrombotic therapy during the acute phase
Critical Timing Considerations
The 2020 ACC Expert Consensus provides clear guidance for patients with cerebrovascular events requiring anticoagulation 1:
For acute stroke patients who need anticoagulation (cardioembolic source), anticoagulation should be initiated between 2-14 days after the acute event, when considered safe from hemorrhagic transformation perspective 1. The exact timing within this window depends on:
- Stroke size: Larger infarcts require longer delays (closer to 14 days)
- Imaging findings: Presence of hemorrhagic transformation on follow-up imaging mandates further delay
- Clinical stability: Neurological worsening suggests waiting longer
Why Stop Everything?
Hemorrhagic transformation risk: Acute ischemic strokes, especially cardioembolic ones involving large vessels like the MCA, have high risk of hemorrhagic transformation. This risk is dramatically amplified by any antithrombotic therapy 1, 2.
DAPT has no role in cardioembolic stroke: The patient's stroke mechanism is cardioembolic, not atherothrombotic. DAPT is indicated for atherothrombotic/noncardioembolic strokes, not cardioembolic ones 2, 3.
Enoxaparin must be stopped: While the patient will ultimately need anticoagulation for their cardioembolic source, therapeutic anticoagulation in the acute stroke period increases hemorrhagic complications without proven benefit 4.
Subsequent Management (After 2-14 Days)
Once the hemorrhagic transformation risk window has passed:
- Start oral anticoagulation alone (DOAC preferred over warfarin) 1
- Do NOT restart antiplatelet therapy - for cardioembolic stroke with anticoagulation indication, antiplatelet therapy should be stopped entirely 1, 2
- The guideline explicitly states: "stopping all APT and treating with an AC alone (DOAC preferred)" 1
Common Pitfalls to Avoid
Do not continue "just aspirin" - even single antiplatelet therapy increases bleeding risk when combined with anticoagulation without providing additional stroke prevention benefit in cardioembolic stroke 1.
Do not restart anticoagulation too early - the 2-14 day window exists because early anticoagulation in acute stroke increases symptomatic hemorrhagic transformation. Patience is critical 1.
Do not assume DAPT was appropriate - if this patient was on DAPT for a recent coronary intervention, that indication becomes secondary to the acute stroke. The stroke takes management priority, and the cardioembolic mechanism means anticoagulation alone (not antiplatelets) is the appropriate long-term therapy 1.
Special Consideration
If this patient had recent PCI with stent placement (reason for DAPT), this creates a complex scenario. However, the acute cardioembolic stroke still mandates stopping all antithrombotics immediately. After the 2-14 day window, if the patient is within 12 months of ACS/stenting, consider anticoagulation plus single antiplatelet (clopidogrel preferred, not aspirin) only if thrombotic risk is deemed extremely high and bleeding risk acceptable 1. Most patients should receive anticoagulation alone.